@nickelpig3
Active 9 months, 1 week ago
Many systemic therapies for advanced hepatocellular carcinoma (HCC) may cause hypothyroidism; however, in these patients, hypothyroidism prevalence before therapy and its prognostic impact remain unclear.
We previously established a prospective cohort of patients who received sorafenib as first-line therapy for advanced HCC. No patients […] View